Pasi A. Jänne, MD
Dana Farber Cancer Institute, 450 Brookline Avenue, LC4114, Boston, MA 02215, USA · Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Pasi A. Jänne, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:32 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT04035486 · A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)AstraZeneca · active not recruiting · Non-Small Cell Lung Cancer · principal investigator
- Ph2NCT03586453 · Osimertinib In EGFR Mutant Lung CancerDana-Farber Cancer Institute · active not recruiting · Carcinoma, Non-Small-Cell Lung
- Ph1NCT02586987 · A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid TumoursAstraZeneca · completed · Lung Cancer, Melanoma, Head and Neck Carcinoma · principal investigator
- Ph1NCT02143466 · AZD9291 in Combination With Ascending Doses of Novel TherapeuticsAstraZeneca · active not recruiting · Advanced Non Small Cell Lung Cancer
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:32 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.